Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jul 31, 2026
Anheuser-Busch InBev (BUD) Posts Solid Q2 Results but China Weakness Sends Shares Down 2%

Anheuser-Busch InBev (BUD) Posts Solid Q2 Results but China Weakness Sends Shares Down 2%

Key Takeaways

  • Revenue and EPS beat estimates: Anheuser-Busch InBev reported Q2 2026 revenue of $16.66 billion (up 5.6% organically) and underlying earnings per share of $1.21, topping consensus estimates of $16.39 billion and $1.12 respectively.
  • Beer volumes returned to growth: Global beer volumes rose 1.1% in the quarter, marking a continuation of positive momentum, while total volumes increased 0.9% year over year.
  • Megabrands and Beyond Beer drove outperformance: Combined revenue from megabrands grew 6.2%, led by Corona (up 17% outside its home market), while Beyond Beer revenue surged 44% and no-alcohol beer climbed 27%.
  • China remained a significant drag: China volumes fell 9.7% in the quarter, driven by adverse weather and persistent weakness in on-premise channels, weighing on investor sentiment.
  • Stock declined despite the beat: BUD shares fell roughly 2% on July 30 as the China headwinds overshadowed an otherwise strong set of global results.
  • Full-year guidance reaffirmed: Management reiterated its fiscal 2026 EBITDA (earnings before interest, taxes, depreciation, and amortization) growth outlook of 4% to 8%.

Why These Earnings Matter

Anheuser-Busch InBev, the world's largest brewer and owner of iconic brands such as Budweiser, Corona, Stella Artois, and Michelob Ultra, delivered its second-quarter 2026 results against a backdrop of uneven global consumer demand. This earnings report carried heightened significance for several reasons: it was the first full quarter to capture the demand uplift from the FIFA World Cup, it provided a reading on whether recent volume stabilization could translate into sustained growth, and it offered a critical update on the company's premiumization and digital transformation strategy. Coming off a strong Q1 in which BUD also exceeded expectations, investors closely watched whether the brewer could maintain momentum across its diverse geographic portfolio, particularly as macroeconomic headwinds persisted in key markets. The results ultimately confirmed the company's operational strength globally while exposing ongoing challenges in China. I also checked comparable names in the sector using Tickeron’s AI Screener to put the results in context.

The Quarter in Detail

For the second quarter ended June 30, 2026, AB InBev reported organic revenue growth of 5.6% to $16.66 billion, comfortably exceeding the analyst consensus estimate of approximately $16.34–$16.39 billion. On a reported basis, revenue increased 11.0%, benefiting from favorable currency translation effects. Revenue per hectoliter rose 4.2%, reflecting disciplined revenue management and a favorable product mix shift toward premium brands.

Underlying earnings per share (EPS) surged 23.4% year over year to $1.21, beating consensus estimates of $1.12 by $0.09. Underlying profit attributable to equity holders reached $2.39 billion, up from $1.95 billion in the same quarter last year. On a reported basis, profit attributable to equity holders jumped to $3.75 billion from $1.68 billion in the prior-year period, supported by non-underlying items.

Normalized EBITDA grew 5.8% to $5.94 billion, with the EBITDA margin expanding 4 basis points to 35.6%, even as the company increased sales and marketing investments. Free cash flow for the first half of 2026 improved dramatically, rising by $2.53 billion to $3.88 billion, reflecting stronger operating profit and improved working capital management. The company's net debt-to-normalized EBITDA ratio improved to 2.86x from 3.27x a year earlier.

Beer volumes returned to growth at 1.1%, while total volumes — including non-beer products — rose 0.9%. Performance was broad-based across four of the company's five geographic zones, with standout results in Middle Americas and South America. The North America segment posted a 2.7% revenue increase, driven by Michelob Ultra, Busch Light, and the Beyond Beer portfolio. However, the Asia Pacific region underperformed, with China volumes declining 9.7% and revenue falling 8.6%, as weak weather and subdued on-premise traffic continued to pressure the business.

Market Reaction

Despite a headline beat on both revenue and earnings, BUD shares declined roughly 2% in premarket and intraday trading on July 30, reflecting a clear tension between the company's global strength and the persistent weakness in its Chinese operations. The stock, which had climbed approximately 33.7% year-to-date and was trading near its 52-week high of $85.56 heading into the report, faced selling pressure as investors digested the magnitude of the China slowdown. AB InBev's Asia Pacific subsidiary, Budweiser APAC, reported that China volumes fell 9.7% and revenue dropped 8.6% in the second quarter, with management acknowledging that more work is needed to stabilize that market. This overshadowed otherwise solid results from Latin America, Europe, and North America. The market's reaction underscores how elevated expectations and the concentrated nature of China's headwinds can weigh on sentiment, even when the broader business is performing well. From what I see, the premiumization trends remain a bright spot worth monitoring closely.

Forward Outlook and What I’m Watching

Management reaffirmed its full-year 2026 EBITDA growth guidance of 4% to 8%, signaling confidence that the underlying business momentum can absorb near-term pressures. The company expects growth to be more evenly balanced between the first and second halves of the year, supported in part by transactional foreign exchange effects that are projected to turn from headwinds into tailwinds, particularly in Mexico and Brazil.

Several factors will be critical for investors to monitor in the months ahead. First, the trajectory of the Chinese market remains the most significant wild card. Management has indicated that the on-premise channel has shown no meaningful improvement through July, and channel inventory levels may continue to decline modestly in the second half. Any stabilization or recovery in China would be a powerful catalyst for sentiment, while further deterioration could continue to weigh on the stock.

Second, the company's premiumization strategy continues to deliver results, with megabrands, no-alcohol beer, and Beyond Beer all posting double-digit growth. The sustained double-digit expansion of Corona, Stella Artois, and Michelob Ultra outside their home markets underscores the global appeal of AB InBev's brand portfolio. Third, the digital ecosystem — particularly the BEES B2B (business-to-business) marketplace, which saw gross merchandise value rise 50% to $1.2 billion — represents a growing source of efficiency and revenue diversification that deserves continued attention.

On the cost side, management flagged potential pressure from unhedged energy and logistics costs in the second half, though disciplined revenue management and premiumization are expected to provide partial offsets. The company's $6 billion share buyback program, of which $1.9 billion had been completed as of July 24, also provides a structural support element for the stock. Lastly, capital expenditures are projected to remain within the $3.5 billion to $4 billion range for the full year, while the normalized effective tax rate is expected to land between 26% and 28%.

Enhancing Research with Tickeron Tools

In my own process, I often turn to Tickeron’s AI Screener when evaluating earnings reports like this one. It helps quickly filter peers by fundamentals, volume trends, and technical signals so I can see how BUD stacks up without spending hours on manual screens. The tool surfaces ideas that align with specific criteria, which I find useful during busy earnings seasons.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: BUD

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


BUD in upward trend: 10-day moving average crossed above 50-day moving average on July 28, 2026

The 10-day moving average for BUD crossed bullishly above the 50-day moving average on July 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BUD advanced for three days, in of 328 cases, the price rose further within the following month. The odds of a continued upward trend are .

BUD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 260 cases where BUD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on August 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BUD as a result. In of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for BUD turned negative on August 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .

BUD moved below its 50-day moving average on August 11, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BUD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating for company is (best 1 - 100 worst), which means the company is slightly undervalued. The valuation of the company is based on a proprietary formula which takes into account a set of fundamentals and gives us an estimate of the price per share for the company. We then compare this estimate with the current price per share. As a result, this company is rated as undervalued in the industry. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.668) is normal, around the industry mean (2.131). P/E Ratio (17.067) is within average values for comparable stocks, (16.910). Projected Growth (PEG Ratio) (1.809) is also within normal values, averaging (2.474). BUD has a moderately low Dividend Yield (0.017) as compared to the industry average of (0.038). BUD's P/S Ratio (2.541) is slightly higher than the industry average of (1.552).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BUD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock slightly better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Anheuser-Busch INBEV SA/NV (NYSE:BUD), Constellation Brands (NYSE:STZ), Molson Coors Beverage Company (NYSE:TAP).

Industry description

The meat, fish, and dairy food industry processes livestock, fish and milk products for consumer consumption. Some companies also process dairy byproducts. Tyson Foods, Inc., Hormel Foods Corporation and Pilgrims Pride Corp. are some of the biggest producers in this industry. Many of these companies are recipients of American farm subsidies. On the other hand, new-age food innovation like plant-based meat substitutes (which are designed to simulate chicken, beef, and pork sausage) could potentially augur disruptions and/or create new competition in this space.

Market Cap

The average market capitalization across the Food: Meat/Fish/Dairy Industry is 39.85B. The market cap for tickers in the group ranges from 317.04K to 159.01B. BUD holds the highest valuation in this group at 159.01B. The lowest valued company is ENHD at 317.04K.

High and low price notable news

The average weekly price growth across all stocks in the Food: Meat/Fish/Dairy Industry was -2%. For the same Industry, the average monthly price growth was 1%, and the average quarterly price growth was -10%. STZ experienced the highest price growth at 3%, while BUD experienced the biggest fall at -7%.

Volume

The average weekly volume growth across all stocks in the Food: Meat/Fish/Dairy Industry was -59%. For the same stocks of the Industry, the average monthly volume growth was -17% and the average quarterly volume growth was -31%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 23
P/E Growth Rating: 60
Price Growth Rating: 56
SMR Rating: 65
Profit Risk Rating: 81
Seasonality Score: -57 (-100 ... +100)
View a ticker or compare two or three
BUD
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a holding company whose subsidiaries manufactures and distributes alcoholic and non-alcoholic beverages

Industry FoodMeatFishDairy

Profile
Details
Industry
Beverages Alcoholic
Address
Brouwerijplein 1
Phone
+32 16276111
Employees
154540
Web
https://www.ab-inbev.com
Interact to see
Advertisement
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.
Golar LNG (GLNG) has remained resilient in recent trading, hovering near the top of its 52-week range as investor interest in floating LNG infrastructure continues to build. The stock is underpinned by a deep FLNG order backlog, steady production from operating assets, and improving financial flexibility.
Liberty Broadband Corporation (LBRDA) has experienced pronounced swings in recent weeks, touching multiyear lows before staging a sharp recovery. The stock continues to trade within a wide 52-week range, closely tied to the value of its Charter Communications stake and investor expectations around the proposed merger.
Apollo Global Management (APO), a leading alternative asset manager, reports Q4 and full-year 2025 results on February 9, 2026, before the market opens. The firm has delivered a year of strong growth, with AUM expanding on record inflows exceeding $200 billion and origination surpassing $300 billion.